Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

A transwoman is struggling with hair loss despite using hormones, dutasteride, and Abiraterone, and is considering making her own treatments due to difficulty accessing them. She has also tried Eucapil and regularly uses Nizoral shampoo.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

ShaneMorcs shared updated hair comparison photos and believes he's made progress. People commented on his improvement, asked about potential side effects, and inquired about the treatments he's using.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

User hears aunt's comment on hair loss during Easter gathering. Others discuss handling rude comments and share experiences with hair loss treatments like Minoxidil and Finasteride.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.

The user experienced eyebrow hair loss and tried various treatments, including Minoxidil, a Capsaicin-based product, Latanoprost, Bimatoprost, Castor Oil, and Travoprost. Despite initial setbacks and a brutal shedding phase, they eventually saw positive results with Travoprost, encouraging others not to give up on treatments.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

The conversation is about using Bimatoprost for hair growth, with concerns about potential side effects like eye color change and fat atrophy. Users discuss combining it with other treatments like Minoxidil and Finasteride, and sourcing Bimatoprost in bulk.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.